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Abstract
Background: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only
effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects
on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience
painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly
understood. Previous studies have demonstrated important roles for TRPV1, TRPM8, and TRPA1 in inflammation
and nerve injury induced pain.
Results: In this study, using real-time, reverse transcriptase, polymerase chain reaction (RT-PCR), we analyzed the
expression of TRPV1, TRPM8, and TRPA1 induced by cisplatin or oxaliplatin in vitro and in vivo. For in vitro studies,
cultured E15 rat dorsal root ganglion (DRG) neurons were treated for up to 48 hours with cisplatin or oxaliplatin.
For in vivo studies, trigeminal ganglia (TG) were isolated from mice treated with platinum drugs for three weeks.
We show that cisplatin and oxaliplatin-treated DRG neurons had significantly increased in TRPV1, TRPA1, and
TRPM8 mRNA expression. TG neurons from cisplatin treated mice had significant increases in TRPV1 and TRPA1
mRNA expression while oxaliplatin strongly induced only TRPA1. Furthermore, compared to the cisplatin-treated
wild-type mice, cisplatin-treated TRPV1-null mice developed mechanical allodynia but did not exhibit enhancement
of noxious heat- evoked pain responses. Immunohistochemistry studies showed that cisplatin-treated mice had no
change in the proportion of the TRPV1 immunopositive TG neurons.
Conclusion: These results indicate that TRPV1 and TRPA1 could contribute to the development of thermal
hyperalgesia and mechanical allodynia following cisplatin-induced painful neuropathy but that TRPV1 has a crucial
role in cisplatin-induced thermal hyperalgesia in vivo.
Background
Painful peripheral neuropathy is the principle dose-lim-
iting factor requiring discontinuation of chemotherapy
with platinum-based drugs such as cisplatin and oxali-
platin [1]. Cisplatin is widely used for treatment of solid
tumors especially against testicular, ovarian, and bladder
cancers [2,3]. Oxaliplatin is a third generation platinum
analogue which is highly effective for metastatic colorec-
tal cancer [4-6]. Platinum-based drugs presumably exert
their antitumor activity by binding to DNA and distort-
ing the helical structure in a way that inhibits transcrip-
tion [7] and induces apoptotic cell death through DNA
damage recognition pathways [8,9]. Up to thirty to forty
percent of cancer patients that receive platinum agents
develop pain and sensory changes, resulting in chronic
dose-limiting peripheral neuropathy [10]. In addition,
oxaliplatin induces distinctive acute cold-associated dys-
esthesia in up to 80% of patients [11]. Current pain
treatments for chemotherapeutic neuropathy have lim-
ited effectiveness, a fact that reflects our poor under-
standing of the underlying pain mechanisms.
Rodent models of platinum-drug induced painful neu-
ropathy have been developed to elucidate the pain
mechanisms caused by platinum drugs [12-14]. Pharma-
cological studies using these models indicate that the
mechanisms underlying mechanical and thermal hyper-
algesia behaviors following platinum drugs are complex
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show that activation and sensitization of nociceptors
plays a key role in pathological pain behaviors following
platinum drugs [18-20]. The putative non-selective
cation channels, transient receptor potential vanilloid 1
(TRPV1), TRPA1, and TRPM8 are the primary detectors
involved in chemical and thermal evoked pain sensation
[21] but the precise contribution of TRPV1, TRPA1,
and TRPM8 in sensitizing nociceptors after cisplatin
and oxaliplatin drugs in vivo is not known.
TRPV1 is a capsaicin receptor that is activated by
painful chemical stimuli, by noxious heat (activated at
42°C), and inflammation, but not by nerve ligation
injury [22-24]. TRPA1 has a functional role in pain and
neurogenic inflammation resulting from channel activa-
tion to a variety of compounds including pungent
agents, irritant chemicals, reactive oxygen and nitrogen
species, and products of oxidative stress-induced lipid
peroxidation [25-33]. TRPA1 has been shown to co-
localize with TRPV1 in subpopulations of DRG and TG
neurons [34,26]. Studies with TRPA1 knockout mice
have demonstrated loss of mustard oil responses in vitro
and in vivo [28,35], and in vivo development of bradyki-
nin-induced mechanical hypersensitivity [35]. TRPA1
has also been implicated as a sensor for painfully cold
temperatures (<17°C) [34,36,37,35] but these findings
are not consistent with others [26,38,28]. TRPM8 is acti-
vated either by menthol or cool temperatures (<27°C)
[39,40] and is involved in cold-evoked responses in vivo
[41,42]. Although the expression of these channels is
increased in other pain models [43-47], it is not yet
known whether platinum drug induced TRPV1, TRPA1,
and TRPM8 expression and functional changes contri-
bute to altered neuronal sensitivity and excitability in
toxic neuropathy.
In the present study, we have used a recently devel-
oped mouse model of cisplatin and oxaliplatin-induced
painful neuropathy [48] to investigate the molecular
mechanisms involved in hyperalgesia after platinum
drug treatment. First, we demonstrate that treatment
with platinum drugs results in the up-regulation of
TRPV1, TRPA1, and TRPM8 mRNA in cultured dorsal
root ganglion (DRG) neurons and that a similar up-reg-
ulation occurs with TRPV1 and TRPA1 following in
vivo treatment with cisplatin although cisplatin-treated
mice had no change in the proportion of TRPV1-immu-
nopositive TG neurons. Oxaliplatin treatment results in
up-regulation of only TRPA1 in vivo. We also illustrate
that up-regulation of TRPV1 and TRPA1 mRNA reflects
increases in TRPV1 and TRPA1 responsiveness in the
nociceptors that contribute to the molecular mechan-
isms of the thermal hyperalgesia and mechanical allody-
nia observed in cisplatin-treated mice. Second, we
demonstrate that TRPV1 is required for mediating heat,
but not mechanical hyperalgesia in cisplatin-induced
nerve injury.
Results and Discussion
Cisplatin and oxaliplatin induced up-regulation of TRPV1,
TRPM8 and TRPA1 mRNA in vitro
Several cellular effects of platinum-based drugs have
been described which may be involved in the develop-
ment of neurotoxicity, including platinum-DNA binding
[49,50] leading to cell cycle alterations and neuronal
death [51], neurite outgrowth inhibition [52,53], vesicu-
lar axonal transport and alteration of microtubule
assembly [54,55]. It remains unclear whether these
changes are the primary factors that trigger a cascade of
events leading to neuronal damage which contributes to
neuropathic pain. In this study we directly measure the
transcripts of the nociceptive TRP channels in sensory
neurons that are likely to be involved in altered pain
response in platinum drug -induced neuropathy.
To elucidate the roles of the hot and cold thermore-
ceptors in sensory neurons, we first assessed TRPV1,
TRPM8, and TRPA1 mRNA expression in rat and
mouse peripheral tissues.S t a n d a r dR T - P C Ro fT R P
mRNA from trigeminal ganglion (TG) and DRG tissues
from naive rat and wild-type mice yielded PCR products
of expected sizes (Figure 1). DRG and TG from rat and
mouse tissues were consistently positive for all three
TRP receptors. 28S RNA mRNA served as control for
the normalization of expression levels.
To determine whether the neurotoxic effects on the
peripheral nervous system from platinum drug exposure
induces changes in the expression of TRPV1, TRPM8,
and TRPA1 mRNA, we used a previously described cell
culture model [50]. Rat E15 DRG neurons were grown
in equimolar concentrations (6.7 μM) of cisplatin or
oxaliplatin, or with vehicle alone. Cells were harvested
at 6, 12, 24, and 48 h after treatment and processed for
TaqMan RT-PCR of TRPV1, TRPM8, and TRPA1
mRNA. Gene expression levels at each time point were
normalized to 28 S RNA and presented as a fold induc-
tion compared to the expression level in vehicle-treated
cells. This quantitative approach enabled comparisons of
the relative changes in expression of each TRP mRNA
in response to platinum drugs at varying time points.
Cisplatin induced significant up-regulation of TRPV1
and TRPA1 mRNA (3-fold) in cultured DRG neurons at
6 h (Figure 2A and 2C). The expression of both TRPV1
and TRPA1 transcripts continued to show increases (6
and 4.5-fold, respectively) at 24 and 48 h (Figure 2A
and 2C). Cisplatin also induced up-regulation of TRPM8
mRNA (2 and 4 fold, respectively) at 24 h and 48 h
(Figure 2B). The transient changes of mRNA levels at 6
h could reflect a reversible short-term neuronal
response to the initial drug effects. These TRP receptors
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damage for protective responses. With prolonged drug
exposure, sustained increase of the TRP transcripts
expression may result from increased long-term neuro-
nal excitability. These data demonstrate a time depen-
dent transcriptional modulation of the expression
pattern of TRP channels on DRG neurons following
exposure to cisplatin. We found a similar effect of plati-
num drugs on the levels of neurotoxicity in DRG neu-
rons in a previous in vitro study [50]. We previously
demonstrated that both cisplatin and oxaliplatin caused
very high levels of platinum-DNA adduct formation in
D R Gn e u r o n si nad o s ea n dt i m e - d e p e n d e n tm a n n e r
but the levels produced by oxaliplatin were 2-3 times
less than those produced by equimolar doses of cisplatin
[50]. In the present study, oxaliplatin mirrors cisplatin
with an early increase of TRPV1 and TRPA1 but inter-
estingly, higher increases of TRPM8 were detected at 24
and 48 h (7.2 and 6.2-fold, respectively). These observa-
tions reveal distinct underlying mechanisms of TRP
channel transcriptional regulation by cisplatin and oxali-
platin in DRG neurons.
Cisplatin induced up-regulations of TRPV1 and TRPA1
mRNA in vivo
To examine whether this phenotype is recapitulated in
vivo, we used TaqMan RT-PCR to look at changes in
TRP channel gene expression in mouse TG tissues har-
vested after 3 weeks treatment with platinum drugs [48].
The use of TG allows the isolation of larger amounts of
tissue than DRG and TG was therefore used as a
surrogate tissue to minimize the number of animals
sacrificed. In this pain model [48], mice were treated
with daily intraperitoneal injection of platinum drugs for
5 days, followed by 5 days of rest, for two cycles. Total
cumulative doses of 23 mg/kg cisplatin and 30 mg/kg
oxaliplatin were used; these doses approximate human
therapeutic doses relative to body weight. Following two
treatment cycles, cisplatin-treated mice developed heat
hyperalgesia and mechanical allodynia. In contrast, oxa-
liplatin-treated mice exhibited only cold hyperalgesia
and mechanical allodynia [48]. In vivo expression data
shown in Figure 2D demonstrates that cisplatin treated-
mice developed significant increases of TRPV1 and
TRPA1 mRNA (7.6 and 11-fold, respectively). In con-
trast, oxaliplatin-treated mice exhibited a significant
increase only in TRPA1 mRNA (6.7-fold). While our
results illustrate that changes in the relative levels of
TRPV1 and TRPA1 mRNA in vivo were similar to those
observed in vitro (Figure 2), the increase in TRPM8
mRNA that was observed in oxaliplatin-treated mice
was less than that seen in vitro. This discrepancy might
simply be due to tissue and species-specific differences.
Moreover, given that we are comparing the tissue
response of ganglia isolated in vivo to culture neurons
isolated from embryonic ganglia, the observed differ-
ences could also be affected by the distinct developmen-
tal age of the preparations or the neuronal environment.
Our present study shows that mice with oxaliplatin-
induced cold hyperalgesia had little change in TRPM8
transcripts expression. Furthermore, a previous beha-
vioral study reported that TRM8
-/- mice still respond
Figure 1 Expression of TRPV1, TRPM8, and TRPA1 mRNA in Rat and Mouse TG and DRG Tissues. Reverse transcribed RNA (0.2 μg) from
TG and DRG tissues of control Sprague Dawley rats (rTG, rDRG) and C57BL/6J wild-type mice (mTG, mDRG) was added to the reaction mixtures
and PCR products amplified in 30 cycles. Control reactions included PCR reactions without reverse transcriptase (-RT). The TRPV1, TRPM8, TRPA1,
28S RNA, and b Actin products were separated on agarose gels and stained with ethidium bromide. Molecular markers (600 and 300 bp ladder)
are as shown.
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another cold-sensitive channel may be involved in this
oxaliplatin-induced cold pain model. In contrast to our
finding, a recent report showed that mice with oxalipla-
tin-induced cold allodynia had increased TRPM8 mRNA
expression [56]. This discrepancy might be due to the
use of different oxaliplatin concentrations (3 mg/kg vs
30 mg/kg), mouse age differences (6 weeks vs 14 weeks),
or differences in the cold testing (acetone vs cold plate)
or mRNA measurement methods (standard vs quantita-
tive RT-PCR). While there is strong evidence supporting
the role of TRPM8 in cold sensation and cooling sub-
stances. The presence and alteration of other ion chan-
nels activated at noxious cold suggests the presence of
TRP-independent mechanisms in oxaliplatin-induced
cold hypersensitivity [57-60]. Future studies can address
the extent of modulation of other ion channels by direct
action of platinum drugs.
Previous behavioral studies have shown that TRPA-/-
mice have normal cold sensitivity [28]. However, we
demonstrate that cisplatin-treated mice have a robust
increase of TRPA1 mRNA without evidence of cold
hyperalgesia suggesting that TRPA1 is unlikely to play a
role in cold nociception in this model. Others have
shown that rats administered with antisense TRPA1
intrathecally showed inhibition to inflammation and
spared nerve injury-induced cold hyperalgesia [36,37]. It
remains to be determined whether these differences are
related to the differences in species or the nerve injury
model.
Both cisplatin and oxaliplatin-treated mice displayed
significant reductions in mechanical pain thresholds and
Figure 2 Platinum drug induced TRPV1 and TRPA1 mRNA up-regulation in vitro and in vivo.I nv i t r oa n di nv i v oe x p r e s s i o no fT R V 1 ,
TRPM8 and TRPA1 mRNA using real-time RT-PCR are shown. Specific TaqMan primers and probe sets were used for the rat or mouse mRNA of
TRPV1, TRPM8, TRPA1, and 28S RNA. The mRNA levels of TRP ion channels are illustrated after normalization to 28S RNA using the 2
-ΔΔCT method
[87] and presented as the ratio of fold change compared to vehicle-treated cells or tissues. In vitro fold increases of TRV1 (A) TRPM8 (B) and
TRPA1 (C) mRNA from rat DRG neurons treated with cisplatin, oxaliplatin, or vehicle across time points 6, 12, 24 and 48 h are shown. Data
represents means ± S.E.M from cDNA prepared from triplicate RNA samples. (D) In vivo fold increases of TRPV1, TRPM8 and TRPA1 mRNA from
TG tissues from cisplatin and oxaliplatin-treated mice compared to vehicle-treated mice after a 3-week drug treatment are shown. Each sample
was from pooled TG from three C57BL/6J wild-type mice after 3-week treatment with cisplatin, oxaliplatin or vehicle. Data represents means fold
increases ± SEM from cDNA prepared from triplicate RNA samples, (***P < 0.001, **P < 0.01, *P < 0.05, two-way ANOVA, post-hoc analysis).
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and 6.7 fold, respectively). Pharmacological studies using
TRPA1 antagonists have shown inhibition of inflamma-
tion and nerve injury-induced mechanical hyperalgesia
in wild-type mice indicating that TRPA1 may contribute
to mechanical transduction in some C-fiber nociceptors
[61-64]. Interestingly, TRPA1 selective inhibitors failed
to reverse inflammation-induced mechanical hyperalge-
sia in TRPA1-/- mice [65]. A potential compensatory
mechanism might explain the masking contribution of
this channel in TRPA-/- mice to maintain the develop-
ment of mechanical hyperalgesia.
While its role in cold and mechanical sensation
remains unclear, there is a growing body evidence that
TRPA1 is a key chemical sensor and is directly activated
by diverse chemicals and the products of cell and tissue
injury [66]. Patients with avulsion injury and diabetic
neuropathy having elevated TRPA1-immunoreactivity in
DRG neurons [67] and with increased levels of reactive
chemicals that are known to be TRPA1 activators
[68,69], confirming that TRPA1 has a role in nocicep-
tion. The behavioral phenotypes that we observe in pla-
tinum drug treated mice are consistent with elevated
levels of expression of TRPV1 and TRPA1 mRNA in
cisplatin-treated mice, and TRPA1 mRNA in oxalipla-
tin-treated mice, implicating TRPV1 and TRPA1 as key
determinants in toxic neuropathy. Future genetic and
pharmacological studies will determine the extent to
which these channels contribute to thermal and chemi-
cal nociception in platinum drug-induced neuropathy.
TRPV1 immunostaining following cisplatin and
oxaliplatin-induced painful neuropathy
To determine whether cisplatin and oxaliplatin induced
changes in TRPV1 protein expression, immunostaining
of TRPV1 protein was performed in the TG of wild-type
mice after a 3-week platinum drug treatment protocol
[48]. We assessed the average percentage of neuronal
profiles expressing TRPV1 per section (Figure 3) and
found an increase in the number of TRPV1 immunor-
eactive profiles in cisplatin-treated mice (24.06 ± 3.65%)
compared to vehicle-treated controls (21.44 ± 4.65%),
but this change was not statistically significant (P =
0.20) (Figure 3). There was a slight decrease in the num-
ber of TRPV1 immunoreactive neuronal profiles in oxa-
liplatin-treated mice (15.92 ± 2.52%; P = 0.04) (Figure
3). To characterize the population of TRPV1-protein
positive neurons, we measured cell soma diameters in
TRPV1-immunoreactive TG cells and observed average
values of 16.66 ± 3.59 μm, 16.04 ± 3.23 μm, 16.99 ±
3.46 μm from vehicle-, cisplatin-, and oxaliplatin-treated
population, respectively. These values also confirmed
that TRPV1 is expressed in small neurons, consistent
with their expression in nociceptors [70,71]. Thus, in
this pain model, cisplatin treatment did not result in an
overall change in the proportion of TRPV1 immunor-
eactive TG neurons.
Cancer patients undergoing chemotherapeutic therapy
with platinum drugs can develop altered pain sensation
resulting from sensory neuropathy [1]. In this study, we
used models of cisplatin and oxaliplatin-induced neuro-
pathy to investigate whether TRPV1, TRPM8, and
TRPA1 mRNA expression were altered along with
changes in thermal sensitivity observed in chemothera-
peutic neuropathy. We show that cisplatin-treated mice
developed heat hyperalgesia along with robustly
increased levels of TRPV1 mRNA expression in TG,
with no change in the proportion of TRPV1 immunopo-
sitive neurons. Furthermore, the increase in TRPV1
mRNA expression in TG in vivo mirrored that observed
in DRG in vitro. We also confirm that cisplatin fails to
influence thermal nociception in TRPV1-/- mice. Thus,
our study provides evidence that up-regulation of
TRPV1 at the transcriptional level is involved in mediat-
ing the heat hyperalgesia observed in mice with cispla-
tin-induced neuropathy.
While TRPV1 is known to play an important role in
heat sensitivity, the mechanisms by which cisplatin-
induced neuropathy affects the channel sensitization are
unclear. Given the increased levels of TRPV1 mRNA
that were found in the sensory nerve cell bodies,
increased TRPV1 expression could result in enhanced
TRPV1 protein trafficking to peripheral terminal noci-
ceptors. Future cisplatin studies will evaluate the levels
of TRPV1 protein expression in intraepidermal nerve
fibers for evidence of cellular trafficking of TRPV1 to
peripheral nociceptor terminals. Previous studies in
inflammation and nerve injury have shown an increase
of TRPV1 protein in DRG and unmyelinated axons in
digital nerves [72,73]. Similarly, inflammation was also
reported to increase the proportion of TRPV1 protein-
positive neurons but not the mRNA level of the TRPV1
receptor in DRGs [74]. This transcription-independent
mechanism of TRPV1 upregulation is found to be
dependent on retrograde transport of NGF acting via
p38 to increase TRPV1 translation in the cell body
which results in increased transport of TRPV1 to per-
ipheral terminals [74]. The participation of TRPV1 in
hyperalgesia resulting from cisplatin-induced neuropathy
might also involve channel phosphorylation by cellular
kinases such as PKC, leading to enhanced TRPV1 sensi-
tivity which contributes to pathological pain [66].
These findings reflect potentially varied mechanisms
of TRPV1 channel sensitization but the nature and ori-
gin of these mechanistic differences remain to be
established.
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similar reduced exploratory activity
Following platinum drug treatment animals were moni-
tored for signs of toxicity with general observations.
Ninety six mice were treated and all survived until the
end of the study with the exception of one cisplatin-
treated wild-type animal that died suddenly at the end
of week four with no evidence of severe general toxicity.
Neither genotype showed alterations of superficial and
core body temperature or signs of nephrotoxicity (data
not shown). Platinum-drug induced peripheral neuro-
toxicity is known to induce body weight loss. Mean
body weight at baseline and post treatment was there-
fore evaluated for both genotypes. Both platinum drugs
had similar temporal effects on body weight of both
genotypes. Cisplatin-treated mice showed a slight but
statistically significant reduction in mean body weight
compared to vehicle-treated mice (Figure 4A). In con-
trast, oxaliplatin-treated mice only show a slight trend
in lower body weight, but this reduction was not statisti-
cally significant (Figure 4A). Treated-mice from both
genotypes gradually regained their initial body weight by
8 weeks after treatment. Animals with experimental
induced neuropathies are frequently seen to have
Figure 3 TRPV1 immunoreactivity following platinum drug treatment. Representative sections of TRPV1 immunoreactivity of TG neurons
from (A) vehicle-, (B) cisplatin-, and (C) oxaliplatin- treated wild-type mice after 3 weeks treatment. Arrows indicate examples of labeled
neuronal profiles. (D) Frequency histogram showing the percentage of labeled TRPV1 profiles in each group. Quantitative analysis of the
proportion of TRPV1 immunopositive TG neuronal profiles stained as shown in (A, B, and C) from vehicle-, cisplatin-, and oxaliplatin-treated
C57BL6J wild-type mice after 3 weeks treatment. Data represents mean ± SD, n = 4 mice/group, (*P < 0.05, two-way ANOVA, Scale bar = 25
μm).
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effect on their peripheral nerves [75,76]. Both platinum
drugs had similar temporal effects on exploratory activ-
ity (Figure 4B) for mice of both genotypes. Cisplatin-
treated mice showed slight decreases in body weight
and locomotor activity, and treated-mice from both gen-
otypes gradually returned to their basal level after drug
cessation. Mice of both genotypes also maintained their
muscle strength and had no evidence of drug effects on
grip strength (data not shown). This mimics the situa-
tion in platinum-treated patients who develop a pure
sensory neuropathy. The absence of cell death or axonal
degeneration in sciatic nerve (data not shown) is also
reflected in the reversibility of nociceptive behaviors
seen in treated mice.
Cisplatin-treated TRPV1-null mice exhibit reduced thermal
hypersensitivity to noxious heat
To determine whether the phenotypes that we
observed at the molecular level are reflected in noci-
fensive behavior, we compared the behavioral
responses of TRPV1
-/- and wild-type mice to different
modalities of stimuli after a 3-week treatment protocol
[48] with cisplatin, oxaliplatin or vehicle alone. Cold
pain is one of the hallmark symptoms of oxaliplatin
acute neuropathy. To determine whether ablation of
TRPV1 alters the balance between hot and cold noci-
ceptors, cold responses in TRPV1
-/- and wild-type
mice were compared after 3 weeks of platinum drug
treatment. Mice were placed on a cold plate calibrated
at -4.2° ± 0.5°C and cold hypersensitivity was measured
as the number of hind paw lifts over a 5-min duration.
Consistent with the intact response of nociceptors to
cold stimuli, we observed no inherent difference in the
number of paw lifts between genotypes at baseline
(Figure 5A). Oxaliplatin treatment induced a robust
cold hypersensitivity in both genotypes. Oxaliplatin
-treated TRPV1
-/- mice had a significant (2-fold)
increase in the number of paw lifts compared to the
vehicle-treated TRPV1
-/- controls (Figure 5A) and this
change in cold response was also observed in the wild-
type mice (Figure 5A). However, this cold hyperalgesia
was only prolonged in the wild-type mice, remaining
statistically significant out to 8 weeks (Figure 5A).
Cold hypersensitivity did not persist in TRPV1
-/- mice.
Cold induced hyperalgesia observed in oxaliplatin-trea-
ted mice therefore mimics the acute, painful dysesthe-
sia reported by more than 80% of patients treated with
oxaliplatin [77].
Previous studies have shown that TRPV1-null mice
have normal basal mechanical sensitivity and normal
mechanical hyperalgesic responses but impaired basal
thermal sensitivity and thermal hyperalgesia following
tissue inflammation [23,24]. Moreover, pharmacological
evidence implicates TRPV1 involvement in mechanical
hyperalgesia in models of inflammatory and neuropathic
pain [78-80]. To determine whether TRPV1 contributes
to the development of mechanical allodynia in this plati-
num drug-induced nerve injury model, mice of both
genotypes were measured for mechanosensory response
after platinum drug treatment. Mechanical response was
evaluated by assessing the withdrawal thresholds to a
calibrated von Frey filament that was applied to the
hind paw. Consistent with the intact response of noci-
ceptors to mechanical stimuli, there was no clear differ-
ence in the basal withdrawal thresholds to mechanical
stimuli between genotypes (Figure 5B), as shown pre-
viously by others [23,81]. Platinum drug treatment
Figure 4 Cisplatin-treated mice show reduced body weight and exploratory activity following each drug treatment cycle.( A )M e a n
body weight of TRPV1
-/- and wild-type mice is reduced after cisplatin drug treatment. (B) Mean horizontal distance traveled in 20 min is reduced
after each cisplatin treatment cycle from TRPV1
-/- and wild-type mice. Data represent the mean ± SEM, n = 7 mice/group (*P < 0.05, ***P < 0.01,
***P < 0.001, two-way ANOVA followed with Bonferroni post hoc analysis; two-tailed unpaired T test for genotypes).
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both genotypes. The withdrawal thresholds were signifi-
cantly reduced for the cisplatin and oxaliplatin-treated
TRPV1
-/- mice, 23% and 20%, respectively (Figure 5B).
This reduction was greater for cisplatin and oxaliplatin-
treated wild-type mice, 40% and 30%, respectively.
While comparable hypersensitivity of mechanical
responses was observed for both genotypes, slightly
greater reduction in withdrawal thresholds was seen in
cisplatin-treated wild-type mice at the later time point
at week 8. This suggests that TRPV1 also participates in
development of mechanical hyperalgesia in platinum
drug-induced pain. Similar findings are also observed in
TRPV1 null mice with intact mechanical hyperalgesia
following inflammation, incision, and tumor-induced
pain [23,82,83]. Interestingly, in acute pharmacological
studies, TRPV1 antagonists appear to reduce mechanical
hyperalgesia which could reflect a compensatory
mechanism with TRPV1-/- mice masking the contribu-
tion of this channel [84].
To test whether TRPV1 is essential for thermal hyper-
algesia in toxic neuropathy, TRPV1
-/- and wild-type
mice were subjected to a Hargreaves radiant heat test
after 3 weeks platinum drug treatment. A radiant heat
source was applied to the hind paw and latency to paw
licking or paw withdrawal was measured. TRPV1-null
mice exhibited a significant 33% increase in mean base-
line withdrawal latency compared to wild-type mice
(Figure 5C). This difference remained relatively
unchanged following treatment with platinum drugs.
However, cisplatin-treated null mice showed transient
hypalgesia after 3 weeks drug treatment. In contrast, cis-
platin significantly reduced radiant heat-evoked withdra-
wal latency in wild-type mice by 40%, 30%, and 20% at
weeks 3, 6, and 8, respectively (Figure 5C). Conversely,
oxaliplatin induced no significant change in withdrawal
Figure 5 Cisplatin-treated TRPV1-null mice exhibit alteredbehavioral responses to noxious heat stimuli. (A) Oxaliplatin-treated TRPV1
-/-
and wild-type mice show an increase in the number of paw lifts to noxious cold stimuli of -4.2°C in a cold plate assay. (B) Cisplatin and
oxaliplatin-treated TRPV1
-/- and wild-type mice exhibit a decreased response threshold to punctate mechanical stimuli to the hind paw in von
Frey assay. (C) Cisplatin-treated TRPV1
-/- mice show no noxious heat-evoked hyperalgesia in the hind paw in a radiant heat assay. In contrast,
cisplatin-treated wild-type mice develop noxious heat-evoked hyperalgesia. (D) Cisplatin-treated TRPV1
-/- mice show no noxious heat-evoked
hyperalgesia in a tail immersion test assay. In contrast, cisplatin-treated wild-type mice develop noxious heat-evoked hyperalgesia. Data represent
the mean ± SEM, n = 7 mice/group (*P < 0.05; ***P < 0.001, two-way ANOVA followed with post hoc analysis; two-tailed unpaired T test for
genotypes).
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role in the response to thermal pain and also signifi-
cantly contributes to heat-evoked nociception after cis-
platin treatment.
A tail immersion paradigm was also used to assess
thermal hyperalgesia in TRPV1-null and wild-type mice
after 3 weeks platinum drug treatment. The distal por-
tion of the tail was immersed in a heated bath and the
time of tail flick was recorded. TRPV1-null mice had a
significant 50% increase of basal withdrawal latencies
compared to wild-type mice (Figure 5D). Similar to the
radiant heat test, cisplatin evoked little change in ther-
mal response in TRPV1-null mice in the tail immersion
test. In contrast, cisplatin treatment evoked consistent
thermal hyperalgesia in the wild-type mice. Significant
45% and 35% decreases in withdrawal latency were
detected for the cisplatin-treated wild-type mice com-
pared to wild-type controls at weeks 4 and 6, respec-
tively. Conversely, no such change was observed for
oxaliplatin-treated mice in either genotype. A clear and
robust impairment in heat evoked responses in both
behavioral heat assays from cisplatin-treated TRPV1-
null mice demonstrates that TRPV1 receptor is an
essential mediator for thermal hyperalgesia in this cis-
platin-induced painful neuropathy model.
Conclusion
Despite their widespread clinical use, the molecular
mechanisms through which platinum drugs mediate their
effects on the nervous system remain unknown. Since
there are distinct differences in the features of the pain
associated with platinum compounds, our goal is to illus-
trate the utility of the recently established mouse model
[48] in distinguishing between the two closely related pla-
tinum drugs in a way that is consistent with clinical obser-
vations. In the present study, we provide evidence that the
up-regulations of TRPV1 and TRPA1 mRNA are coupled
with enhanced heat and mechanical hypersensitivity in cis-
platin-treated mice. In addition, the up-regulation of
TRPA1 mRNA is observed with enhanced cold and
mechanical hypersensitivity in oxaliplatin-treated mice.
Thus, TRPV1 and TRPA1 are likely to have an important
role in nociceptive processing in platinum drug-induced
painful neuropathy. We also show that TRPV1
-/- mice dis-
play deficits in thermally evoked pain-related behaviors
but are not insensitive to noxious heat. These results indi-
cate that TRPV1 plays a crucial role in signaling heat-
induced pain after cisplatin-induced nerve injury.
These results may further define the biology TRP
channels and their role in platinum drug-induced neuro-
pathy which could provide potential targets for treat-
ment strategies to ameliorate neuropathic pain in these
debilitating diseases.
Methods
Experimental animals and drugs treatment
This study was conducted with the approval of the
Mayo Clinic Animal Care and Use Committee and in
compliance with the regulations of the National Insti-
tutes of Health and the ethical guidelines of the Interna-
tional Association for the Study of Pain [85].
M a l eC 5 7 B L 6 Jm i c ew e r eu s e da n dw e r eo r d e r e da t
least two weeks prior to study to allow for housing
adjustment. For TRPV1
-/- studies, B6.129X1-Trpv1
tm1Jul/
J mice were obtained from the Jackson Laboratory (Bar
Harbor, ME) and propagated at Mayo Clinic Animal
Husbandry. All behavioral studies for both genotypes
were done on male mice. Mice were housed in cages of
four in an enriched environment. Mice were 13-14 weeks
old and weight was 24-26 g when the study began. All
mice had free access to water and food and were exposed
to a standard light cycle of 12 hours on and 12 hours off.
Cisplatin and oxaliplatin-induced painful neuropathy
model
After habituation to the test environment and baseline
measurements of pain sensitivity, mice were randomized
to three treatment groups of either cisplatin (2.3 mg/
kg), oxaliplatin (3.0 mg/kg), or vehicle (0.9% saline).
Mice were treated with daily intraperitoneal injection (i.
p.) for 5 days, followed by 5 days of rest, for two cycles.
Total cumulative doses of 23 mg/kg cisplatin and 30
mg/kg oxaliplatin over a total of ten injections were
used as previously described [48].
Behavioral assays
All the behavioral studies were performed with the
operator were blinded to the genotype and status of
drug treatment. The activity assay, cold plate assay, von
Frey assay, radiant heat assay, and tail immersion assay
were all conducted as previously described [48] and as
described briefly below.
Activity monitoring
Monitoring of locomotor activity was carried out at
b a s e l i n e ,d u r i n gd r u gt r e a t m e n ta tw e e k s1 ,2 ,3 ,a n d
after treatment at weeks 6, 8, and 10 using VersaMax
Animal Activity Monitors (AccuScan Model RXYZCM-
16, Columbus, OH). Although the VersaMax monitor
collects information in 21 behavioral categories, we only
analyzed distance traveled in 20 min, collected in 1-min
intervals, collapsed into 10 2-min blocks, averaged and
presented as group means ± SEM. Data were analyzed
by a VersaMax Analyzer (AccuScan Model CDA-8,
Columbus, OH).
Cold plate assay
For the assessment of cold hyperalgesia, we used a Pel-
tier-cooled cold plate preset at -4.2° ± 0.2°C with a
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metal plate (TECA, Chicago, IL) and counted the num-
ber of paw lifts in 5 min. For each cold testing session,
mice were brought to the testing room and allowed to
acclimate for 10 min prior to being placed individually
onto the cold metal surface enclosed in a clear plexiglass
b a r r i e ro f8c mW×1 4c mD×1 4c mHw i t hat o p
cover. To insure the accuracy of paw lift counting, we
videotaped each cold plate testing session using a video
camcorder (Sony DCR-PC1000) and replayed in slow
motion. The total number of brisk lifts of either hind
paw, or jumping, was counted as a response to cold
hyperalgesia. Movements associated with locomotion
were distinct, involving coordinated movement of all
f o u rl i m b sa n dt h e s ew e r ee x c l u d e d .M i c ew e r eo n l y
tested once on any given test day to avoid any possible
anesthetic or tissue damage effects that could be pro-
duced by repeated exposure to a cold surface. A maxi-
mum cut off time of 5 min was used to prevent tissue
damage. Three separate trials were carried out on three
separate days at base line and two separate trials during
and after drug treatment at weeks 1, 3, 6, and 8 were
averaged and presented as the mean number of paw lifts
± SEM.
Von Frey filament assay
For the measurement of mechanical allodynia, we used
an Ugo Basile Dynamic Plantar Aesthesiometer (Stoelt-
ing, Wood Dale, IL) using the von Frey filament princi-
ple. Mice were placed under clear plastic boxes above a
wire mesh floor that allowed full access to the paws.
Acclimation and exploratory behavior were observed for
up to two hours until mice became calm and close to
motionless. Paw movement associated with locomotion
or weight shifting was not counted as a withdrawal
response. Paw withdrawal thresholds from eight trials,
from both hind paws of each mouse, were averaged and
recorded as mean ± SEM.
Radiant heat assay
For the assessment of paw thermal hyperalgesia, a radi-
ant heat assay was conducted using a Plantar Ugo Basile
apparatus (Stoelting, Wood Dale, IL). Mice can move
freely in this apparatus on an elevated glass surface with
plastic boxes above as the top cover. Mice are given a
two hour acclimation period prior to testing until they
become calm and motionless. Each hind paw was tested
alternately with an interval of 5 min for four trials. Paw
withdrawal latencies from eight trials, from both hind
paws of each mouse, were averaged and recorded as
mean ± SEM.
Tail immersion assay
For examining tail thermal hyperalgesia, a tail immer-
sion test was conducted with the water bath preset at
50.5° ± 0.5°C. Latency to vigorous tail flick was recorded
during three trials separated by at least 30 min and the
three trials were averaged and presented as mean ±
SEM. Cutoff time was set at 20 s, after which the mouse
was removed regardless of behavioral response.
Cell Culture for In Vitro Real-Time RT-PCR
Timed pregnant female Sprague-Dawley rats (Harlan,
Madison, WI) were anesthetized with sodium pentobar-
bital and E15 rat pups were isolated for dissection of
spinal ganglia of cervical, thoracic, lumbar, and sacral
regions as previously described [50]. Only three experi-
mental conditions were carried out at a time. For each
experimental condition, 280-320 DRG from 7-8 rat pups
were rapidly isolated, dissociated, and the neurons were
plated onto rat tail collagen (BD Biosciences, Indianapo-
lis, IN) in a coated 10 cm culture dish (Falcon™,F i s h e r
Scientific) at a density of approximately 2 × 10
6 cells/
dish. Each experimental condition was performed in tri-
plicate. Cells were cultured for the first 24 h in Eagle’s
minimal essential medium (EMEM) medium along with
other basic supplements. After 24 h, cultures were
grown in the above medium supplemented with 1 × 10
-
5 M 5-Fluorodeoxy-2-uridine and 1 × 10
-5 M uridine for
5 days to remove supporting cells. After 48 hours of
equilibration with normal medium, cultures were rando-
mized to one of three experimental conditions: 6.7 μM
(2 μg/ml) cisplatin, 6.7 μM( 2 . 6μg/ml) oxaliplatin, or
media alone. Cultures were harvested for RNA isolation
after 6, 12, 24, and 48 h of drug treatment. Oxaliplatin
(Sigma-Aldrich, St. Louis, MO) was dissolved in sterile
distilled water (1 mg/ml). Pharmaceutical grade cisplatin
(1 mg/ml) was obtained from Bristol-Myers Squibb
Company (Princeton, NJ).
Tissues Preparation for Standard and Real-Time RT-PCR
For standard RT-PCR, separate groups of four naïve
adult male rats Sprague Dawley (Harlan, Madison, WI)
and eight naïve adult male mice C57BL/6J (Jackson
Lab, Maine) were deeply anesthetized with sodium
pentobarbital (50 mg/kg i.p.) and left and right TG
and DRG tissues were quickly dissected from each ani-
mal. For real-time RT-PCR, separate groups of twenty
seven wild-type mice, nine from each treatment group
(cisplatin, oxaliplatin, vehicle), were anesthetized with
sodium pentobarbital (50 mg/kg i.p.) 24 h after com-
pletion of a 3-week drug treatment protocol, then left
and right TG tissues were rapidly dissected and
removed from each animal. The nine mice from each
treatment group were divided three groups of three
mice each and TG from these groups were pooled and
processed for triplicate samples. The collected TG tis-
sues were quickly placed on dry ice and stored at -80°
C prior to RNA isolation. It was necessary to pool the
tissue to prevent significant loss of RNA during the
extraction procedure.
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For in vitro real-time RT-PCR, total RNA was isolated
from rat DRG using a column homogenizer (Qiagen
Shredder, Qiagen Inc., CA) and an RNeasy Mini Plus
Kit (Qiagen Inc., CA) according to the manufacturer’s
directions. For standard RT-PCR and in vivo real-time
RT-PCR, total RNA was isolated from rat and mouse
DRG and TG tissues using a tissue homogenizer (Ten-
broeck, Fisher Scientific) and an RNeasy Lipid Tissue
Mini Kit (Qiagen Inc., CA) according to the manufac-
turer’s directions. Samples were DNase treated with
RNA-free DNAse (Qiagen Inc., CA) and quantified on a
NanoDrop 1000 spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE, USA) prior to proceeding
with standard and real-time RT-PCR. RNA quality and
integrity, which can substantially affect the outcome of
real-time RT-PCR measurements, was verified by elec-
trophoretic analysis using a Bioanalyzer 2100 (Agilent
Technologies, Palo Alto, CA) by Mayo Molecular Core
Facility and all samples had RNA integrity (RIN) values
of 8.5-9.5. RIN values of 8 or higher are considered per-
fect for downstream RNA applications [86].
Standard RT-PCR
To detect TRPV1, TRPM8, and TRPA1 mRNA expres-
sion in sensory neurons, TG and DRG tissues from
control rats and mice were isolated for RNA extraction
followed by RT-PCR and gel electrophoresis. Total
RNA was reverse transcribed into cDNA using Molo-
n e yM u r i n eL e u k e m i aV i r u sR e v e r s eT r a n s c r i p t a s e
with oligo (dT) and random hexamers as primer
(iScript cDNA Synthesis Kit, BioRad, CA). The reverse
transcription (RT) reaction was performed in a 40 μl
solution of 8 μl 5× iScript Reaction Mix, 2 μli S c r i p t
Reverse Transcriptase, and 0.2 μgR N A .N e g a t i v ec o n -
trols (without reverse transcriptase) were included.
The RT condition was performed at 25°C for 5 min-
utes, 42°C for 30 minutes, and 85°C for 5 minutes
using a MyIQ™ thermal cycler (BioRad, CA). The
synthesized cDNA products were then used directly as
templates for PCR amplification. The PCR reaction
was performed in a 25 μl solution containing 20 μlo f
PCR Supermix (Platinum Supermix High Fidelity, Invi-
trogen), with 5 picomoles primers, and cDNA (20 ng -
200 ng). PCR amplification was performed for 30
cycles. Following an initial hot start of 2 minutes at
94°C, each cycle consisted of 1 min of denaturation at
94°C, 1 min of annealing at 56°C, and 1 min of exten-
sion at 72°C using a MyIQ™ thermal cycler (BioRad,
CA). Each sample was run in duplicate. The amplified
PCR products were separated by electrophoresis on a
2% agarose gel containing ethidium bromide and were
visualized with UV illumination.
Taqman Real-Time RT-PCR
Reverse transcription of 400 ng mRNA was performed
with the iScript cDNA Synthesis Kit (BioRad, CA) accord-
ing to manufacturer’s instructions as described above.
Taqman PCR assays were performed in triplicate on sam-
ples of cDNA from rat DRG neurons (in vitro real-time
PCR) or from mouse TG tissues (in vivo real-time PCR)
and were carried out in 96-well optical plates (BioRad,
CA) using a MyIQ™ thermal cycler (BioRad, CA). Each
real-time RT-PCR was repeated with at least an additional
independent run with different cells or tissue cDNA sam-
ples. Real-time PCR reactions consisted of cDNA product
( 2 0n g-2 0 0n g ) ,1 0μMp r i m e r ,1 0μMT a q m a np r o b e ,
and 12.5 μl 2× BioRad IQ SuperMix (#170-8860, IQ
Supermix, BioRad, CA) in a total volume of 20 μl. Amplifi-
cation was performed for 51 cycles. Following an initial
hot start of 3 minutes at 95°C, each cycle consisted of 15 s
of denaturation at 95°C, and 1 min of annealing at 60°C.
Control reactions included PCR reactions on DNase RNA
(without RT) and reactions run without templates to test
for contamination. Oligonucleotide probes were serially
diluted in nuclease-free water to produce a standard curve
relating threshold cycle to template copy number. The
threshold cycle, which represents the PCR cycle at which
an increase in reporter fluorescence above background is
first detected, was determined by the software (MyIQ,
BioRad, CA) based on the generated standard curves. All
essays showed a linear correlation between cycle threshold
and amplicon in serial dilution experiments. Only PCR
reactions run with efficiency in the range of 98% to 100%
were included for calculations. The relative quantification
of real time RT-PCR products was performed using the 2
-
ΔΔCT method [87]. The fold change of mRNA expression
levels of target genes TRPV1, TRPM8, and TRPA1 were
normalized to 28S RNA as the reference gene, followed by
normalization to controls. Data is presented as fold induc-
tion of platinum-drug treated cells or tissues compared to
the expression level in vehicle-treated cells or tissues. Each
target gene was considered to be differentially expressed
when the Livak’s calculation yielded an average fold differ-
ence of at least ± 2.0 compared to reference gene.
Oligonucleotides
For standard RT-PCR, the primers specific for rat and
mouse TRPV1, TRPM8, TRPA1, b-actin, and 28S RNA
were designed using Primer Express software (Applied
Biosystems, Foster City, USA) (Table 1). For real-time
RT-PCR, the primers and Taqman probes specific for
r a ta n dm o u s eT R P V 1 ,T R P M 8 ,T R P A 1 ,a n d2 8 SR N A
were designed using the Roche Universal Library Assay
Design Center (Roche Applied Science, Indianapolis)
(Table 2). Each primer set produced nucleotide ampli-
con corresponding to the specific Roche probe catalog
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Indianapolis) (Table 2). Primers used in this study are
listed in table 1 and table 2 with gene name, accession
number, primer orientation, sequence (5’ to 3’), and pro-
duct size in base pairs.
Immunohistochemical staining of TRPV1 in Trigeminal
Ganglia
Male mice were transcardially perfused (n = 4 for each
group) with 4% paraformaldehyde with 01% pircric acid
i n0 . 1Mp h o s p h a t eb u f f e r( P B )a t4 ° Ca n dt h e
trigeminal ganglia (TG) on both sides were removed
and placed overnight in 30% sucrose-PB. Using a cryo-
stat (Microm, Germany), the TG were sectioned at 8
μm through the short axis and mounted on 3 well
Teflon-coated, gelatin dipped slides (Electron Micro-
scopy Sciences, Hatfield, PA). For accuracy each ganglia
was measured before cutting and sections were collected
at 6 equally spaced intervals throughout the entire
length. The sections were immunostained for TRPV1 by
first permeabilizing the membrane by rinsing in 0.1 M
phosphate buffered saline (PBS) with 0.2% triton X-100
Table 1 Oligonucleotide Sequences of Primers Used for Standard RT-PCR
Rat TRPV1 NM_031982 Forward GGTGTGCCTGCACCTAGC 107 bp
Reverse CTCTTGGGGTGGGGACTC
Rat TRPM8 NM_134371.2 Forward GCCCAGTGATGTGGACAGTA 64 bp
Reverse GGACTCATTTCCCGAGAAGG
Rat TRPA1 NM_207608.1 Forward ATTTGCGGCCTGAGTTTTT 68 bp
Reverse TCCATCATTGTCCTCATCCA
Rat 28S RNA V01270 Forward GACAGGTTAGTTTTACCCTACTGATGA 74 bp
Reverse CCTGCGGTTCCTCTCGTA
Rat b-actin NM_031144.2 Forward CCCGCGAGTACAACCTTCT 72 bp
Reverse CGTCATCCATGGCGAACT
Mouse TRPV1 NM_001001445 Forward TTGGATTTTCCACAGCCGTAGT 155 bp
Reverse GAACTTGAACAGCTCCAGACATGT
Mouse TRPM8 NM_134252 Forward CCAAATCACAATGAGGTCACAGC 185 bp
Reverse CTTCAGGTGTAAAGTCCTCTGTACACTT
Mouse TRPA1 NM_177781 Forward ATTGTTCTCATGAACTTACTGATTGGCT 186 bp
Reverse CCTGGGTCTATTTGGATACACGAT
Mouse b-actin NM_007393 Forward ACCCACACTGTGCCCATCTA 342 bp
Reverse GCCACAGGATTCCATACCCA
Table 2 Oligonucleotide Sequences of Primers Used for Real-Time RT-PCR
Rat TRPV1 NM_031982 Forward GGTGTGCCTGCACCTAGC 107 bp
Reverse CTCTTGGGGTGGGGACTC
Rat TRPM8 NM_134371.2 Forward GCCCAGTGATGTGGACAGTA 64 bp
Reverse GGACTCATTTCCCGAGAAGG
Rat TRPA1 NM_207608.1 Forward ATTTGCGGCCTGAGTTTTT 68 bp
Reverse TCCATCATTGTCCTCATCCA
Rat 28S RNA V01270 Forward GACAGGTTAGTTTTACCCTACTGATGA 74 bp
Reverse CCTGCGGTTCCTCTCGTA
Mouse TRPV1 AB180097.1 Forward ACCACGGCTGCTTACTATCG 68 bp
Reverse TCCCCAACGGTGTTATTCAG
Mouse TRPM8 NM_134252 Forward TCAGATACACAGAGATCCTTCTGC 75 bp
Reverse GGCTCCCTCGAAGGACAT
Mouse TRPA1 NM_17778.21 Forward CCATGACCTGGCAGAATACC 73 bp
Reverse TGGAGAGCGTCCTTCAGAAT
Mouse 28S RNA X00525.1 Forward GGCCACTTTTGGTAAGCAGA 143 bp
Reverse GCGGATTCCGACTTCCAT
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perature (RT) in 10% normal goat serum in PBS.
Sections were incubated overnight at RT in goat anti-
TRPV1 (1:1000, catalog no. sc-12498, Santa Cruz Bio-
technology, Santa Cruz, CA). Following 3 rinses in PBS,
the sections were placed for 1 h in donkey anti-goat IgG
cyanine 3 (Cy3) conjugate (1:400, Jackson ImmunoRe-
search, West Grove, PA). After rinsing again in PBS the
sections were coverslipped with Vectashield (Vector
Labs, Burlingame, CA). The specificity of this antibody
was previously assessed by incubating sections in anti-
serum pre-absorbed with the corresponding peptide
(100 μg peptide/1 ml antiserum). None of the sections
immunostained with this solution showed positive
immunofluorescence [88]The total number of neuronal
profiles in each section was determined by counterstain-
ing adjacent sections with 1% cresyl violet.
Analysis of TRPV1 staining in the Trigeminal Ganglia
The study was blinded so the investigator was unaware
of what treatment group was being analyzed. After
staining, color digitized images of sections to be ana-
lyzed (24 bits per pixel), were captured using the 20×
objective on an Olympus BX51 microscope with Cy3 fil-
ter cube and an attached Spot RT digital camera (Diag-
nostic Instruments, Sterling Heights, MI). Camera
exposures were adjusted automatically by Spot software
(version 3.1) and brightness and gamma corrections
were made manually to achieve the best signal-to-noise
ratios. Percentages of TRPV1-labeled neuronal profiles
were calculated by dividing the number of labeled pro-
files by the total number of TG profiles in the section x
100. An average was then obtained for the 6 sections of
tissue analyzed for each animal.
The diameters of TG neurons were calculated by sum-
ming the length and width of those neurons with a visi-
ble nucleus and dividing by two. Approximately 200
neurons were measured from the 4 mice in each group.
Data are presented as an average ± SD.
Statistical analyses
Immunohistochemical data are presented as the mean ±
standard deviation (SD), all other data are expressed as
mean ± standard error of the mean (SEM). Results were
illustrated and analyzed using Graphpad Prism version 4
(Graphpad Software, San Diego, USA). Statistical analyses
on behavioral studies were performed using two-way
ANOVA with drug treatments and time as independent
variables to examine the differences in response across
treatment groups. Follow-up analysis was conducted
using the Bonferroni test. For comparisons between wild
type and TRPV1 null mice, two-tailed unpaired Student’s
t tests were used. For immunohistochemical data, differ-
ences among groups were analyzed with a two-way
ANOVA. P value of less than 0.05 is considered statisti-
cally significant.
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